<DOC>
	<DOCNO>NCT00631878</DOCNO>
	<brief_summary>`` Phase I/II , Randomized , Double Blind , Placebo Controlled , Dose Escalating , Safety Pharmacokinetics Study Very Low Birth Weight Neonates Four Doses BSYX-A110 Prevention S. epidermidis Infection . '' The purpose study evaluate safety pharmacokinetics escalate dos BSYX-A110 administer Study Days 0 14 .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study VLBW Neonates With BSYX-A110</brief_title>
	<detailed_description>`` Phase I/II , Randomized , Double Blind , Placebo Controlled , Dose Escalating , Safety Pharmacokinetics Study Very Low Birth Weight Neonates Four Doses BSYX-A110 , Human Chimeric Anti-Staphylococcal Monoclonal Antibody Prevention S. epidermidis Infection '' first study BSYX-A110 target population hospitalize , low birth weight infant . The purpose study evaluate safety pharmacokinetics escalate dos BSYX-A110 administer Study Days 0 14 . This randomized , double blind , placebo control , dose escalate study BSYX-A110 48 low birth weight neonate . The dose level evaluate 10 , 30 , 60 90 mg/kg . Each dose level enroll 12 infant receive two dos BSYX-A110 placebo intravenously ratio 2:1 hospitalized follow birth . Infants follow 8 week follow first dose BSYX-A110 placebo . The primary objective study evaluate safety tolerability . The secondary objective analyze pharmacokinetics BSYX-A110 . Positive culture obtain study period record analyze .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must meet follow criterion time first infusion ( Day 0 ) : 1 . 37 day age , inclusive 2 . Birth weight 7001300 gram 3 . Survival expect least 1 week infusion 4 . Inpatient Neonatal Intensive Care Unit intravenous access 5 . Written inform consent obtain parent ( ) guardian Multiple gestation : 1 . Siblings multiple gestation may enrol meet entry criterion 2 . No 4 subject birth weight dose cohort may siblings Patients may none follow either first second dose : 1 . Clinically overt systemic infection , determine history , physical examination , culture laboratory data . Neonates know suspected HIV infection without active systemic infection exclude . 2 . Life threaten hemodynamic instability 3 . Severe congenital anomaly genetic disorder ( especially predispose cardiac decompensation ) determine history and/or physical examination include limited : i. Trisomy 13 ii . Trisomy 18 iii . Hypoplastic Left Heart Syndrome iv . Omphalocele v. Gastroschesis vi . Holoprosencephaly 4 . Known suspected hepatic renal insufficiency 5 . Persistent seizure disorder 6 . Immunodeficiency due prematurity 7 . A history immune globulin administration prior first study drug infusion 8 . Any history , infant subject mother , hypersensitivity severe vasomotor reaction immunoglobulin G , blood product . 9 . Any following laboratory finding 1 . BUN creatinine &gt; 1.5 x upper limit normal age 2 . AST ( SGOT ) , ALT ( SGPT ) total bilirubin &gt; 1.5 x upper limit normal age 3 . Direct bilirubin &gt; 2.0 mg/dL 4 . Hemoglobin &lt; 9.0gm/dL 5 . White Blood Count &lt; 2,000 cells/mm3 10 . Currently receive recently receive investigational agent could interfere conduct result study . Each patient receive investigational agent review investigator designee Sponsor prior patient 's entry study . 11 . Expectation patient able follow duration study . 12 . Mother serology positive hepatitis B surface antigen 13 . Receipt Hepatitis B vaccine since birth</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Staphylococcal</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Very Low Birth Weight Infants</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>